Bubble Baby Families Denied ‘Compassionate Use’ of Live-Saving Therapy
By David Jensen,
Substack
| 05. 25. 2021
Update 5/28: Orchard Exits Life-Saving Bubble-Baby Research in Wake of Flap Over Patient Access
A gene therapy company backed by millions of dollars from the state of California has withheld “compassionate use” of a life-saving therapy sought by parents of children suffering from what is known as the bubble baby disease, according to a patient advocate group and parents.
The families sounded an “SOS” this spring in a letter to the company, Orchard Therapeutics PLC.
“We implore you to treat this as a desperate call for help to save young lives,” the letter said. More than 20 young children are in “urgent need of gene therapy for ADA-SCID (the medical term for the bubble baby disease),” the letter said. (See text here.)
Disclosure of the rejection of the compassionate use treatment is a new twist in the story about the gene therapy, which has saved some 50 lives during its experimental development for bubble babies. The news is likely to intensify criticism of the company for its financially driven decisions concerning the bubble baby disease.
The rare affliction is...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
